Current status of Bexxar for treatment of non-Hodgkin's lymphoma

Immunotherapy using monoclonal antibodies to specifically target B cells has provided new strategy to many patients with indolent lymphomas. Lymphomas are extremely sensitive to radiation, and significant progress has been made over the last decade in the development of radioimmunotherapy with ¹³¹I labeled anti-CD20 antibodies(Bexxar).